User:Mr. Ibrahem/Ublituximab

Ublituximab, sold under the brand name Briumvi, is a medication used to treat multiple sclerosis. Specifically it is used for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is given by injection into a vein.

Common side effects include infusion reactions and upper respiratory tract infections. Other side effects may include infections and low immunoglobulins. Use during pregnancy may harm the baby. It is a monoclonal antibody directed against CD20.

Ublituximab was approved for medical use in the United States in 2022. In 2023 it received a positive opinion by regulators in Europe. In the United States it costs about 64,000 USD per year as of 2023.